Can KRAS-Targeted Immunotherapy Change Outcomes in Resected Pancreatic Cancer? "Eileen O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase 2 AMPLIFY-7P trial evaluating camupepimut (ELI-002 7P) in resected KRAS-mutated pancreatic ductal adenocarcinoma (PDAC). Dr. @EileenMOReilly discusses the significance of ctDNA status, the relationship between immune activation and clinical benefit, and how these findings may inform future phase 3 development of KRAS-targeted immunotherapy in pancreatic cancer." From @GiOncNow gioncologynow.com/videos/can…

I am running for the ASCO Board out of a deep commitment to an organization that has shaped my career. A belief that through collective engagement & shared leadership, we can expand opportunities, inform policy, advance care, and improve the lives of all people with cancer,

PRABITAS phase III trial pragmatic trial enrolled 972 pts in 17M evaluating the schedule of TAS-102 + bev (2 weeks on/2 weeks off) vs. (1 week on/1 week off) which validates non-inferiority and less dose reductions validating our RWD approach in the US. #colorectal #cancer #ESMO2026 @OncoAlert

Interim analysis of HARMONi-GI1 phase III findings of #Ivonescimab (bispecific Ab for PD-1/VEGF) + chemo vs. durvalumab + chemo for treatment-naive #biliarytract #cancer (N=682). 👏👏 🔹Primary endpoint: OS of 14.9M vs. 12.1 (HR = 0.75) 🔹PFS: 8.4 vs. 5.8M; HR = 0.61 🔹ORR = 53.8% vs. 32.5% 🔹Subsequent therapies was 31.8% vs. 45.9% (more so in control arm) @curecc #cancer #cancerresearch @OncoAlert @SMMT_TX

CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal #cancer vs. investigators choice (N=594) Primary endpoints: PFS + OS 🔹OS: 10M vs. 5M (HR = 0.47) 👏 🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line) 🔹 12M 42.6% in 2nd line 🔹 ORR: 23.3% vs. 13.8% 🔹PFS: HR = 0.77 was NS in 2L+ 🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+ 🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting #ESMO2026 @OncoAlert #cancerresearch @AstraZeneca

Grateful to present 3 posters at #ESMO2026 in Madrid! 🇪🇸 1. Pathogenic germline ATM alterations define a distinct pancreatic cancer subtype with improved survival, less liver metastases and reduced KRAS signaling. @CentralParkWMD @EileenMOReilly @ciacobu @CpcrMsk 2. POSTN+ fibroblasts identify an aggressive tumor microenvironment and poorer survival in pancreatic cancer (#PRODIGE24). @RemyNicolle @cros_jerome 3. Early CT-derived body composition changes predict survival in biliary tract cancer patients receiving immunotherapy, independently of radiological progression, CA19-9, ECOG PS, and weight loss (#PRODIGE57). @DelayeMatthieu Grateful to all collaborators at @MSKCancerCenter, @institut_curie, and GERCOR/PRODIGE! #PancreaticCancer #GIOncology

PD(L)1-VEGF bispecifics are already beating PD1 inhibition alone in trials, so what's next? This trial (BioNTech, DualityBio, BMS) adds a new B7-H3 ADC to a PDL1-VEGF bispecific, with potential synergy: 1) VEGF blockade: normalizes tumor vasculature, improves ADC delivery and T cell infiltration. 2) B7-H3 ADC: kills cancer cells, triggers immunogenic inflammation. 3) PDL1 blockade: releases immune suppression, allows T cells to exploit immune response induced by ADC. Confirmed ORR up to 71% -- in immune-cold platinum-resistant ovarian cancer. The broader, ongoing phase 2 includes colorectal cancer, pancreatic cancer and other tumor types.

#ESMO26 Day 1 highlight for me: MASTERPLAN, now in Lancet Oncology. Radiation and pancreatic cancer have a complicated history. ESPAC-1 suggested adjuvant chemoradiation hurt. LAP07 and CONKO-007 couldn't show an OS benefit after chemo. A021501 closed its RT arm for futility. PREOPANC-2 was a draw. We walked through the adjuvant side of this story in Sem Rad Onc last year: doi.org/10.1016/j.semradonc.… So why is MASTERPLAN different? Phase 2, 14 sites in Australia and NZ (can i just say I love the Aus-NZ studies). 74 patients with high-risk localized PDAC, randomized 2:1 to chemo ± SBRT 40 Gy/5 after induction. 12-mo locoregional recurrence 20.2% vs 52.0%, sHR 0.44, p=0.022 
PFS 11.9 vs 6.3 mo, HR 0.44 
OS 22.0 vs 14.0 mo, HR 0.45 
Grade ≥3 AEs 70% vs 64%. Why did this one work when others didn't? The rad oncs can explain the physics better than I can. I just read it as better tumor zap zap. Does it change practice? Maybe. I think we need to have a deeper conversation at every tumor board, but the juice seems worth the squeeze. @OncoAlert @TheGutOncLab @Onco_Nexus sciencedirect.com/science/ar…

Some tentative good news today for a vaccine in pancreas cancer. - 7-valent mutant KRAS vaccine (G12D, G12R, G12V, G12A, G12C, G12S and G13D) given after surgery and completion of chemotherapy (with or without radiotherapy) in patients with stage I-III KRAS-mutant pancreas cancer. - This did not prevent recurrence in the overall population. - But, when split into pre-specified groups: ctDNA+ vs. ctDNA-, or presence/absence of prior radiation, there was significant (and substantial) protection. - It's unclear how this KRAS vaccine will interact with KRAS inhibitors in the future. The vaccine is made by Elicio Therapeutics, the data were presented by Eileen O'Reilly at ESMO - it's now moving to phase 3.

fda.gov/drugs/resources-info… Congratulations to @AndreaCercek & Luis Diaz on their practice changing work, now finally reflected in an FDA approval for locally advanced rectal cancer. We are now curing these patients with limited toxicity. Lucky to have you as colleagues and mentors.

Preprint of one of my main postodoc projects over the last 5 years, mentored by @SantoshVardhana, which nominates inflammation-mediated iron deficiency as a metabolic bottleneck limiting anti-tumor CD8+ T cells immunity. Full tweetorial below by Santosh.

#daraxonrasib clinical outcomes by allele in #RASolute302 from FDA NDA review. These data perpetuate unresolved questions: - is RASi as effective for KRAS WT; K12R? See Table 24; Fig 11. - is 300 mg necessary for maximal clinical benefit? no data provided comparing 200 vs 300.

After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine

Phenomenal oral and poster presentations by rising star Kate Ryan on the impact of selective ablation of basal-like and classical pancreas cancer cells on the TME. @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @dana_peer @TuomasTammela

Lucky to have had the opportunity to work with @WeillCornell Medicine Resident Jennifer Guo who has led the @MSKCancerCenter institutional analysis of ctDNA platform concordance in pancreas cancer KRAS detection. @MSK_DeptOfMed @CpcrMsk

Great work by very talented @WeillCornell medical student Emma Cismas on the impact of organ dysfunction on trial enrollment, treatment practices and outcomes in pancreatic cancer at @AACR Pancreas. @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk

🧵 1/10 The arc: POLAR - MDF – TIE Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors. Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control. That led us to two questions: #1 👆🏼what makes these tumors immunogenic? #2 ✌️what makes that immunity actually work? 👑 #2. POLAR TIE @biorxivpreprint biorxiv.org/content/10.64898… #1. MDF biorxiv.org/content/10.64898… #0. POLAR @NatureMedicine nature.com/articles/s41591-0… #cancer #immunotherapy #PancreaticCancer #ICI #BRCA #HRD #3episodes @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ldiaz1971 @debschrag @PanCAN @oncodaily @OncoDailyGI @OncoAlert @OncBrothers @brunolarvol

Excited to speak at the 2026 International Symposium of Gastrointestinal Oncology (ISGIO), taking place October 2-3 in Fort Lauderdale, FL. Chaired by @EileenMOReilly @GIcancerDoc I'd love to see you there. Use code PARK for free registration: gotoper.com/isgiofof26 Yes, Central PARK @CentralParkWMD So many exciting clinical and scientific advances are changing how we treat GI cancers! 🔬💫 This multidisciplinary conference brings together leading experts to discuss new advances in GI cancer research and care. It's a great opportunity for oncologists, surgeons, nurses, and other GI cancer health care professionals to connect and dive into the latest treatment data and clinical strategies. #RAS #KRAS #GIOncology #GICancer #PrecisionOncology #CancerResearch #ClinicalTrials #pancsm

Thank you @wolfblitzer and @CNN for highlighting this milestone for #PancreaticCancer 💜 For more than four years I’ve had the privilege of helping develop daraxonrasib clinically and leading translational research while caring for patients with previously treated advanced disease. Some have had exceptional responses lasting years. Children’s weddings. Grandchildren’s graduations. Long-planned travels. Seeing these moments become possible has been a true joy in my clinic. That is what more time means. Now I lead MSK’s participation in RASolute-303 to test daraxonrasib as initial treatment for metastatic disease. Across the field we are also developing next-generation RAS inhibitors and degraders and testing novel combinations and treatment in earlier-stage disease. Our goal is to make this benefit deeper and longer-lasting for our patients. Grateful to fellow investigators including @EileenMOReilly and all the international investigators, our clinical and research teams and above all our courageous patients and families. This is why we do this work. And this is just the beginning. @CpcrMsk @MSK_DeptOfMed @RevMedicines @PanCAN @OncBrothers @OncoAlert @oncodaily @OncoDailyGI @lustgartenfdn

Now FDA finally delivered!! Please welcome 🎂 the new birth of 💫 “RASONque” Congrats 🎉🎊 to every investigator, nursing teams, research teams and courageous patients! #pancreaticcancer #PDAC @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @EileenMOReilly @MichaelMayMD @MarcHilmi @FiyinfoluB @schoenfeld_j @AnupriyaSingha9 fda.gov/news-events/press-an…